Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
Research Square|September 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialWungki Park, Catherine O'Connor, Joanne Chou, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapySebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Clinical Lung Cancer|January 23, 2024
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational ResearchArsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, et al.
The Lancet. Oncology|June 6, 2022
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry studyDavid J Pinato, Juan Aguilar-Company, Daniela Ferrante, et al.
Therapeutic Advances in Medical Oncology|November 15, 2021
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registryLaia Garrigós, Cristina Saura, Clara Martinez-Vila, et al.
Eclinicalmedicine|July 12, 2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational studyMelissa Bersanelli, Elena Verzoni, Alessio Cortellini, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Nature Medicine|March 26, 2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trialWungki Park, Catherine A O'Connor, Joanne F Chou, et al.
The Lancet. Oncology|March 10, 2023
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registryAlessio Cortellini, Josep Tabernero, Uma Mukherjee, et al.
Pageof 11